Stability Testing Summit

Boston, MA, United States

This conference will address both the business and scientific aspects of stability testing. As organizations look to streamline operating costs and reduce time to market, stability testing executives will have an opportunity to gain insights into how real-life conditions can impact the supply chain, testing facilities, operating costs, formulations, manufacturing processes, packaging, and analytical methods.

Top Five Reasons to Attend:

  1. Discover innovative approaches to product stability testing & validation
  2. Identify ways to ensure your organization has an advanced, compliant process that exceeds the expectations of regulators
  3. Ensure the long-term stability of both final formulations as well as active and inactive ingredients
  4. Evaluate testing methods and tactics when working with new gene and cell therapies
  5. Learn how to minimize the loss of revenue and save resources when dealing with disruptions in your supply chain

Who Should Attend:

  • Stability Testing
  • Analytical Testing
  • Stability Management
  • Quality Control
  • Quality Assurance
  • Development and Manufacturing
  • QA/QC
  • Stability Laboratories
  • Raw Materials
  • Laboratory Management
  • Regulatory Affairs
  • Formulation
  • Drug Delivery
  • Drug Discovery
  • Manufacturing Technology
  • Clinical Pharmacology
  • Formulation/Preformulation
  • Pharmaceutical Development
  • Preclinical Development
This program is also of interest to:
  • Formulation Specialists
  • Drug Delivery Specialists
  • Excipient Manufacturers/Suppliers
  • CROs


  • Joshua T. Ayers, Ph.D., Stability Manager, ASTRAZENECA
  • Tyson Chasse, Ph.D., Senior Director Analytical Sciences, CMC, AGIOS PHARMACEUTICALS
  • Anthony Chikere, Ph.D., MSAT-BT Process Mgmt. & Systems, BAYER PHARMACEUTICALS, BERKELEY CALIFORNIA
  • Heather Egland, Stability Coordination Manager, FRESENIUS KABI USA
  • Timothy Forsyth, Ph.D., MSAT BT Process Mgmt. and Systems, BAYER PHARMACEUTICALS, BERKELEY CALIFORNIA
  • Chris Latoz, Manager Stability and Analytical Services, HOLLISTER INCORPORATED
  • Peju Odunusi, Ph.D., Group Leader, Stability, ABBOTT VASCULAR
  • Jeremy Pariseau, Stability Scientist, SANOFI
  • Amy St. Charles, Senior Principal Scientist/Group Leader of Biotherapeutics Stability, Reference Materials and Raw Materials, PFIZER
  • Chris Vitkun, Analytical Chemist/Stability Systems, A&Z PHARMACEUTICALS, INC.
  • Kayla Woodlief, Senior Manager, Biologics Stability and Analytics, BIOGEN INC.


Hyatt Regency Boston Harbor
101 Harborside Drive
Boston, MA 02128

To make reservations, please call 1-888-421-1442 and request the negotiated rate for ExL's September Meetings. To make reservations online Click Here

The group rate is available until September 3, 2019. Please book your room early, as rooms available at this rate are limited.